SCHEMBL8460947

SCHEMBL8460947

CC(C)c1cccc(C(C)C)c1NC(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.81

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.81
KMT2A Q03164 2/20 0.81
SMN1; SMN2 Q16637 1/20 0.53
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
MEN1 O00255 1/20 0.47
SOAT2 O75908 1/20 0.47
SOAT1 P35610 1/20 0.47
FFAR1 O14842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16591365 0.95 LMNA (0.74) LMNAKMT2ASMN1; SMN2GAAHTT
SCHEMBL4315481 0.90 LMNA (1.00) LMNAKMT2ASMN1; SMN2GAAHTT
Hydrochloric Acid SCHEMBL28857355 0.88 LMNA (0.97) LMNAKMT2ASMN1; SMN2GAAHTT
Iodide SCHEMBL30758614 0.88 LMNA (0.97) LMNAKMT2ASMN1; SMN2GAAHTT
SCHEMBL19138403 0.85 KMT2A (0.73) LMNAKMT2ASMN1; SMN2MEN1
SCHEMBL14788839 0.84 LMNA (0.71) LMNAKMT2ASMN1; SMN2GAAHTT
SCHEMBL24574897 0.83 LMNA (0.85) LMNAKMT2ASMN1; SMN2GAAHTT
SCHEMBL31155751 0.83 LMNA (0.69) LMNAKMT2ASMN1; SMN2HTTSOAT2
SCHEMBL24574896 0.83 LMNA (0.69) LMNAKMT2ASMN1; SMN2MEN1
SCHEMBL8461958 0.82 LMNA (0.59) LMNAKMT2ASMN1; SMN2GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049387-B1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & CO (US) 2020-11-11 EP disclosed
US-9200142-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9200144-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9200142-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9193845-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-11-24 US disclosed
US-9120914-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-09-01 US disclosed
US-20150094406-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-04-02 US disclosed
US-20150087759-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 US disclosed
US-20150087757-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 US disclosed
US-20150087757-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 US disclosed
US-20150087758-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY 2015-03-26 US disclosed
US-8951647-B2 Organic electroluminescence device MERCK PATENT GMBH (DE) 2015-02-10 US disclosed
WO-1999048529-A1 RETINOID-GLITAZONE COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-30 WO disclosed
EP-0808159-A1 USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1997-11-26 EP disclosed
WO-1996024344-A1 USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1996-08-15 WO disclosed
US-5489611-A ADMINISTERING A RETINOID COMPOUND WARNER-LAMBERT COMPANY (US) 1996-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087757-A1 THERMOPLASTIC POLYMER COMPOSITION PARG, PUF60, MCM7 LMNA 347/4885KMT2A 1047/4885SMN1; SMN2 933/4885
US-20150087758-A1 THERMOPLASTIC POLYMER COMPOSITION ERCC4, SMCHD1, XRCC5 LMNA 855/4885KMT2A 1432/4885SMN1; SMN2 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.